AstraZeneca prevails in inhaler dispute
ricochet64 / Shutterstock.com
In a win for Mylan Pharmaceuticals, a US Court of Appeals for the Federal Circuit panel has ruled it can revisit a decision that held the generic maker infringed patents covering AstraZeneca's inhaler asthma treatment, Symbicort.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Mylan, patents, AstraZeneca, construction, claim, Symbicort, Turbohaler, Federal Circuit, remand, generic, asthma, treatment